WILMINGTON, DE — AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA (albuterol/budesonide) in reducing the risk of severe ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

The China National Medical Products Association (NMPA) has approved AstraZeneca's Fasenra (benralizumab) as a maintenance treatment for individuals aged 12 years and older with severe eosinophilic ...

AstraZeneca is capping out-of-pocket costs for inhalers and related medication at no more than $35 per month, the drugmaker announced Monday. The Britain based pharma giant said the expanded ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis Phase IIIb clinical development of Airsupra was conducted by Avillion under ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...

by Les Luchter, March 23, 2025 ; Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first ...

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating cardiovascular disease. Airsupra, AstraZeneca's asthma drug, shows promise in ...

After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is adding to the thesis that the drug can cut the risk of asthma exacerbations regardless of disease ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...

Major pharmaceutical companies have agreed to cap out-of-pocket costs for some asthma patients at $35 per month, a move that offers relief but doesn't fully address the larger issue of high drug ...